Herschorn, S, Stothers, L, Carlson, K, Egerdie, B, Gajewski, JB, Pommerville, P, Schulz, J, Radomski, S, Drutz, H, Barkin, J, Paradiso-Hardy, F. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 2010; 183(5): 1892–1898.CrossRefGoogle ScholarPubMed

Wagg, A, Dale, M, Tretter, R, Stow, B, Compion, G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013; 64(1): 74–81.CrossRefGoogle ScholarPubMed

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar

Buser, N, Ivic, S, Kessler, TM, Kessels, AG, Bachmann, LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol, 2012; 62(6): 1040–1060.CrossRefGoogle ScholarPubMed

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar

Kessler, TM, Bachmann, LM, Minder, C, Löhrer, D, Umbehr, M, Schünemann, HJ, Kessels, AG. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011; 6(2): e16718.CrossRefGoogle Scholar

Oxybutynin. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar

Oxybutynin. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 31 December 2022 via www.micromedexsolutions.com.Google Scholar

Summary of product characteristics – Ditropan 2.5 mg tablets. Neon Healthcare Ltd. Electronic Medicines Compendium: Ditropan 2.5 mg tablets – summary of product characteristics (SmPC) – (emc). Accessed on 31 December 2022 via www.medicines.org.uk.Google Scholar

Vouri, SM, Kebodeaux, CD, Stranges, PM, Teshome, BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2017; 69: 77–96.CrossRefGoogle ScholarPubMed

Wagg, A, Gibson, W, Ostaszkiewicz, J, Johnson, T 3rd, Markland, A, Palmer, MH, Kuchel, G, Szonyi, G, Kirschner-Hermanns, R. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn 2015; 34(5): 398–406.CrossRefGoogle ScholarPubMed

Welk, B, McClure, JA. The impact of anticholinergic use for overactive bladder on cognitive changes in adults with normal cognition, mild cognitive impairment, or dementia. Eur Urol Open Sci 2022; 46: 22–29.CrossRefGoogle Scholar

Yoo, DS, Han, JY, Lee, KS, Choo, MS. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. Int J Clin Pract 2012; 66(2): 132–138.CrossRefGoogle Scholar